Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic

PURPOSE: The COVID-19 pandemic changed diagnostic and treatment pathways in oncology. We compared the safety and efficacy of pembrolizumab amongst advanced nonsmall cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) ≥ 50% before and during the pandemic. METHODS: Advanced NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ksienski, Doran, Gupta, Sapna, Truong, Pauline T., Bone, Jeffrey, Chan, Angela, Alex, Deepu, Hart, Jason, Pollock, Philip, Patterson, Tiffany, Clarkson, Melissa, Dissanayake, Dushanthi, Sonke, Eric, Lesperance, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281358/
https://www.ncbi.nlm.nih.gov/pubmed/35834010
http://dx.doi.org/10.1007/s00432-022-04181-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281358/
https://www.ncbi.nlm.nih.gov/pubmed/35834010
http://dx.doi.org/10.1007/s00432-022-04181-0

Ejemplares similares